Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011-2016.

Introduction, Materials And Methods: We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHADS-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban.

Results: In total, 53,860 AF patients were included (VKA 37.7%, dabigatran 24.